Vistagen Therapeutics Stock Fundamentals
| VTGN Stock | USD 2.73 0.15 5.81% |
VistaGen Therapeutics fundamentals help investors to digest information that contributes to VistaGen Therapeutics' financial success or failures. It also enables traders to predict the movement of VistaGen Stock. The fundamental analysis module provides a way to measure VistaGen Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to VistaGen Therapeutics stock.
At this time, VistaGen Therapeutics' Depreciation And Amortization is very stable compared to the past year. As of the 26th of November 2024, Total Other Income Expense Net is likely to grow to about 3.8 M, while Interest Expense is likely to drop about 25.1 K. VistaGen | Select Account or Indicator |
VistaGen Therapeutics Company Return On Equity Analysis
VistaGen Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current VistaGen Therapeutics Return On Equity | -0.62 |
Most of VistaGen Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, VistaGen Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
VistaGen Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, VistaGen Therapeutics has a Return On Equity of -0.6152. This is 97.43% lower than that of the Biotechnology sector and 98.31% lower than that of the Health Care industry. The return on equity for all United States stocks is 98.45% higher than that of the company.
VistaGen Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining VistaGen Therapeutics's current stock value. Our valuation model uses many indicators to compare VistaGen Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across VistaGen Therapeutics competition to find correlations between indicators driving VistaGen Therapeutics's intrinsic value. More Info.VistaGen Therapeutics is rated second in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At this time, VistaGen Therapeutics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the VistaGen Therapeutics' earnings, one of the primary drivers of an investment's value.VistaGen Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses VistaGen Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of VistaGen Therapeutics could also be used in its relative valuation, which is a method of valuing VistaGen Therapeutics by comparing valuation metrics of similar companies.VistaGen Therapeutics is currently under evaluation in return on equity category among its peers.
VistaGen Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of VistaGen Therapeutics from analyzing VistaGen Therapeutics' financial statements. These drivers represent accounts that assess VistaGen Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of VistaGen Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 19.3M | 183.5M | 245.5M | 25.1M | 22.5M | 21.4M | |
| Enterprise Value | 22.0M | 84.1M | 180.4M | 11.1M | 10.0M | 9.5M |
VistaGen Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, VistaGen Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to VistaGen Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
VistaGen Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (77.74) % | ||||
| Current Valuation | (19.91 M) | ||||
| Shares Outstanding | 27.84 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 53.63 % | ||||
| Number Of Shares Shorted | 528.16 K | ||||
| Price To Earning | (0.66) X | ||||
| Price To Book | 0.82 X | ||||
| Price To Sales | 86.58 X | ||||
| Revenue | 1.06 M | ||||
| Gross Profit | (227.3 K) | ||||
| EBITDA | (32.45 M) | ||||
| Net Income | (29.36 M) | ||||
| Cash And Equivalents | 51.99 M | ||||
| Cash Per Share | 0.25 X | ||||
| Total Debt | 2.12 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 3.44 X | ||||
| Cash Flow From Operations | (25.81 M) | ||||
| Short Ratio | 2.62 X | ||||
| Earnings Per Share | (0.74) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 39 | ||||
| Beta | 0.78 | ||||
| Market Capitalization | 75.87 M | ||||
| Total Asset | 123.65 M | ||||
| Retained Earnings | (356.21 M) | ||||
| Working Capital | 115.55 M | ||||
| Current Asset | 6.91 M | ||||
| Current Liabilities | 1.8 M | ||||
| Net Asset | 123.65 M |
About VistaGen Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze VistaGen Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of VistaGen Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of VistaGen Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 791 K | 920.2 K | |
| Total Revenue | 1.1 M | 1.1 M | |
| Cost Of Revenue | 568 K | 539.6 K | |
| Stock Based Compensation To Revenue | 2.05 | 2.15 | |
| Sales General And Administrative To Revenue | 13.22 | 12.56 | |
| Research And Ddevelopement To Revenue | 18.82 | 19.76 | |
| Capex To Revenue | 0.06 | 0.07 | |
| Revenue Per Share | 0.05 | 0.05 | |
| Ebit Per Revenue | (31.03) | (29.48) |
Pair Trading with VistaGen Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if VistaGen Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in VistaGen Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with VistaGen Stock
| 0.91 | VALN | Valneva SE ADR | PairCorr |
| 0.64 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against VistaGen Stock
The ability to find closely correlated positions to VistaGen Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace VistaGen Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back VistaGen Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling VistaGen Therapeutics to buy it.
The correlation of VistaGen Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as VistaGen Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if VistaGen Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for VistaGen Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out VistaGen Therapeutics Piotroski F Score and VistaGen Therapeutics Altman Z Score analysis. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.74) | Revenue Per Share 0.029 | Quarterly Revenue Growth (0.34) | Return On Assets (0.39) | Return On Equity (0.62) |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.